Depression predicts the pattern of cognitive impairment in early Parkinson's disease

Faculty of Philology, University of Belgrade, Beograd, Central Serbia, Serbia
Journal of the Neurological Sciences (Impact Factor: 2.26). 11/2006; 248(1-2):131-7. DOI: 10.1016/j.jns.2006.05.031
Source: PubMed

ABSTRACT To estimate the pattern of cognitive impairment in early Parkinson's disease (PD) associated with depression. Also, the prediction of potentially relevant demographic/clinical factors in early PD on cognitive functioning was tested.
The study comprised 80 consecutive early PD patients (16 with major depression (PDMD), 10 PD patients with dysthimic disorder (PDDD), and 54 nondepressed PD patients (PDND)). Thirty_seven healthy subjects matched for age, gender and education were also included in the study. The cognitive evaluation included the comprehensive classical neuropsychological battery and the Cambridge Neuropsychological Test Automated Battery (CANTAB).
The two different patterns of cognitive impairment in early PD patients were obtained even when the confounding influences of general cognitive abilities and motor slowness were taken in account. One pattern was common to all PD patients either they were depressed or not, and it is conceived etiologically as dysexecutive. The PDDD group presented only the quantitative increment of the common deficit observed in PD. The second pattern was present in PDMD patients, involved episodic/working memory and language deficits alongside with background executive impairment. Depression was extensively associated with the cognitive dysfunction in early PD, whereas severity of the disease, age at onset and treatment were less favorable as predictors.
This study provides evidence that the pattern of cognitive impairment in early PD may be predicted by depression severity. Therefore, the recognition and treatment of depressive disorder in early PD is important.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors describe neuropsychological outcomes in people with Parkinson's disease (PD) after their participation in an NIH-sponsored, randomized, controlled trial of cognitive-behavioral treatment for depression. Improvements in mood were associated with modest gains in verbal memory and executive functioning over the 10-week treatment period and accounted for greater variance in neuropsychological outcomes at the end of treatment than other known correlates of cognitive functioning in PD, such as disease severity, age, and education. Baseline working memory and executive skills were also associated with depression improvement over time.
    The Journal of neuropsychiatry and clinical neurosciences 11/2013; DOI:10.1176/appi.neuropsych.12120381 · 2.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To examine the effects of Tai Chi exercise (TCE) on depression, quality of life and self-efficacy in patients with Parkinson's disease (PD). Method: A nonequivalent control-group pre and posttest design was used. Of the 30 participants 15 were assigned to the experimental group and 15 to the control group. The experimental group participated in 8 weeks of TCE which included one day of exercise with instructor on site and 3 days of self-exercise at home guided by a videotape. Results: The 8 weeks of TCE were found to be significantly effective in enhancing quality of life and self-efficacy. However there was no significant difference in the level of depression. Conclusion: These results suggest that TCE has positive effect on quality of life and self-efficacy in patients with PD. Research over an extended period with the TCE intervention is recommended to identify further effects.
    01/2008; 15(4).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives We examine the associations of adherence to antiparkinson drugs (APDs) with health care utilization and economic outcomes among patients with Parkinson’s disease (PD). Methods By using 2006–2007 Medicare administrative data, we examined 7583 beneficiaries with PD who filled two or more APD prescriptions during 19 months (June 1, 2006, to December 31, 2007) in the Part D program. Two adherence measures— duration of therapy (DOT) and medication possession ratio (MPR)—were assessed. Negative binomial and gamma generalized linear models were used to estimate the rate ratios (RRs) of all-cause health care utilization and expenditures, respectively, conditional upon adherence, adjusting for survival risk, sample selection, and health-seeking behavior. Results Approximately one-fourth of patients with PD had low adherence (MPR < 0.80, 28.7%) or had a short DOT (≤400 days, 23.9%). Increasing adherence to APD therapy was associated with decreased health care utilization and expenditures. For example, compared with patients with low adherence, those with high adherence (MPR = 0.90–1.00) had significantly lower rates of hospitalization (RR = 0.86), emergency room visits (RR = 0.91), skilled nursing facility episodes (RR = 0.67), home health agency episodes (RR = 0.83), physician visits (RR = 0.93), as well as lower total health care expenditures (−$2242), measured over 19 months. Similarly, lower total expenditure (−$6308) was observed in patients with a long DOT versus those with a short DOT. Conclusions In this nationally representative sample, higher adherence to APDs and longer duration of use of APDs were associated with lower all-cause health care utilization and total health care expenditures. Our findings suggest the need for improving medication-taking behaviors among patients with PD to reduce the use of and expenditures for medical resources.
    Value in Health 03/2014; 17(2):196–204. DOI:10.1016/j.jval.2013.12.003 · 2.89 Impact Factor